• Disciplinary proceedings opened against Croatian Football Federation
  
• Fowl Ball” Could Be A Huge Hit For Young Sluggers
  
• New Chief Executive of the Meat Hygiene Service appointed
  
• Sale of British Airways Travel Clinic
  
• Lufthansa resumes flights to Beirut
  
• Partnership for Change with Air Navigation Service Providers, Cost Efficiency, Environment
  
• Head-to-head study comparing Lexiva® to Kaletra presented at IAC 2006 and published in The Lancet
  
• Eli Lilly and Company Announces Approvable Letter Issued by FDA for Arxxant TM
  
• Medicines, money and motivated health workers are key...
  
• Skindividual preserve skin’s youthful beauty
  
• A weekend in Paris
  
• Fifth Annual EA Sports Madden Challenge Starts September 1st to...
  
• Akamai and Instant Media Team to Deliver Seamless High-Definition Internet Video Experience
  
• Teva Announces Launch of Generic Zoloft®
  
• Zoller Wine Styling Offers Custom Made Premium Winemaking
  

Teva Provides Generic Biaxin® Xl Update

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it launched Teva s generic Biaxin® (Clarithromycin) XL Filmtabs® last Friday following the decision rendered on Thursday June 22, 2006 by the U.S. Court of Appeals for...

the Federal Circuit vacating a June 2005 ruling which had granted Abbott s motion for a preliminary injunction related to the product.

In a related development, late yesterday, June 26, 2006, Abbott filed an emergency motion in the U.S. District Court for the Northern District of Illinois, where the patent infringement case is pending with a trial scheduled for March 2007, to enjoin Teva from further sales of the product pending additional appeals despite the vacatur of the
preliminary injunction. In order to permit this motion to be presented to the judge most familiar with the case, Abbott agreed to a briefing schedule concluding on Thursday, June 29, 2006 and Teva agreed to refrain from further sales of this product pending the outcome of the motion.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80% of Teva s sales are in North America and Europe.

Teva Pharmaceutical Industries Ltd.

• Teva Announces Launch of Generic Zoloft®
  
• Teva Provides Generic Biaxin® Xl Update
  
• Teva Announces Tentative Approval for Generic Cozaar® Tablets
  
• Teva Provides Update on Generic Pravachol Exclusivity
  
• Teva Comments on Pfizer Press Release Regarding Azithromycin
  
• Teva Announces Approval of Cefprozil Tablets and Cefprozil for Oral Suspension Usp
  
• Teva and Ivax Receive European Commission Approval for Acquisition
  
• Teva and Barr Announce Launch of Generic Allegra® Tablets by Teva Under Agreement With Barr
  
• Court Grants Teva Summary Judgment of Non-Infringement on Gabapentin
  
• Teva Announces Tentative Approval of Granisetron Hydrochloride Injection